Drugs for Lipid Storage Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 45)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bezafibrate |
Approved, Investigational |
Phase 4 |
|
41859-67-0 |
39042 |
Synonyms:
2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionate
2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
Azufibrat
Azupharma brand OF bezafibrate
Bayer brand OF bezafibrate
Befibrat
Befizal
Béfizal
Berlin chemie brand OF bezafibrate
Berlin-chemie brand OF bezafibrate
Betapharm brand OF bezafibrate
Beza lande
Beza puren
Bezabeta
Bezacur
Bezafibrat
Bezafibrat PB
BEZAFIBRATE
Bezafibrate azupharma brand
Bezafibrate bayer brand
Bezafibrate berlin-chemie brand
Bezafibrate betapharm brand
Bezafibrate cryopharma brand
Bezafibrate elfar brand
Bezafibrate hennig brand
Bezafibrate hexal brand
Bezafibrate isis brand
Bezafibrate lakeside brand
Bezafibrate merckle brand
Bezafibrate roche brand
Bezafibrate synthelabo brand
Bezafibrate tad brand
Bezafibrate teva brand
Bezafibrato
Bezafibratum
Bezafibric acid
Bezafisal
BEZAGEN XL
|
Beza-lande
BezaLande
Bezalip
Bezalip®
BEZALIP-MONO
Bezamerck
Beza-puren
BezaPuren
Bezatol SR
BEZATOL SR (TN)
BM 15.075
BM-15.075
BM-15075
Boehringer mannheim brand OF bezafibrate
Cedur
Cryopharma brand OF bezafibrate
Difaterol
Durabezur
Elfar brand OF bezafibrate
Eulitop
FIBRAZATE XL
Hennig brand OF bezafibrate
Hexal brand OF bezafibrate
Isis brand OF bezafibrate
Lakeside brand OF bezafibrate
LIPAROL XL
Lipox
Merckle brand OF bezafibrate
PB, Bezafibrat
Reducterol
Regadrin b
Roche brand OF bezafibrate
Sklerofibrat
Solibay
Synthelabo brand OF bezafibrate
TAD brand OF bezafibrate
Teva brand OF bezafibrate
ZIMBACOL XL
|
|
2 |
|
Clofibric Acid |
|
Phase 4 |
|
882-09-7 |
2797 |
Synonyms:
2-(4-Chlorophenoxy)-2-methylpropionate
2-(4-Chlorophenoxy)-2-methylpropionic acid
2-(p-Chlorophenoxy)-2-methylpropionate
2-(p-Chlorophenoxy)-2-methylpropionic acid
2-(p-Chlorophenoxy)isobutyrate
2-(p-Chlorophenoxy)isobutyric acid
4-CPIB
a-(4-Chlorophenoxy)-a-methylpropionate
a-(4-Chlorophenoxy)-a-methylpropionic acid
a-(p-Chlorophenoxy)isobutyrate
a-(p-Chlorophenoxy)isobutyric acid
Acide (p-chlorophenoxy)-2 methyl-2 propionique
Acide clofibrique
Acido clofibrico
Acidum clofibricum
alpha-(4-Chlorophenoxy)-alpha-methylpropionate
alpha-(4-Chlorophenoxy)-alpha-methylpropionic acid
alpha-(p-Chlorophenoxy)isobutyrate
alpha-(p-Chlorophenoxy)isobutyric acid
Chlorfibrinate
|
Chlorfibrinic acid
Chlorofibrinate
Chlorofibrinic acid
Chlorophibrinate
Chlorophibrinic acid
Clofibrate
Clofibrate free acid
CLOFIBRIC ACID
Clofibric acid free acid
Clofibrinic acid
Clofibrinsaeure
CPIB
p-Chlorophenoxyisobutyrate
p-Chlorophenoxyisobutyric acid
PCIB
PCPIB
Α-(4-chlorophenoxy)-α-methylpropionate
Α-(4-chlorophenoxy)-α-methylpropionic acid
Α-(p-chlorophenoxy)isobutyrate
Α-(p-chlorophenoxy)isobutyric acid
|
|
3 |
|
Nicotinamide |
Approved, Investigational |
Phase 3 |
|
98-92-0 |
936 |
Synonyms:
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
Acid amide
Amid kyseliny nikotinove
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra brand OF niacinamide
Austrovit PP
b 3, Vitamin
b3, Vitamin
Benicot
beta-Pyridinecarboxamide
b-Pyridinecarboxamide
Delonin amide
Dipegyl
Dipigyl
Endobion
Enduramide
Factor PP
FREEDERM
Hansamid
Inovitan PP
Jenapharm brand OF niacinamide
Jenapharm, nicotinsäureamid
m-(Aminocarbonyl)pyridine
Mediatric
Merck brand OF niacinamide
NAM
Nandervit-N
Niacevit
Niacin
Niacinamide
Niacinamide astra brand
Niacinamide jenapharm brand
Niacinamide merck brand
Niacinamide pharmagenix brand
Niamide
NIATIN
Niavit PP
NICAM
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
|
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamide
Nicotinamidum
Nicotinate amide
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsäureamid jenapharm
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Niocinamide
Niozymin
NSC-13128
NSC-27452
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix brand OF niacinamide
PP-Faktor
Propamine a
PYRIDINE-3-CARBOXAMIDE
Pyridine-3-carboxylic acid amide
Savacotyl
Vi-nicotyl
Vi-noctyl
Vitamin b 3
Vitamin b3
Vitamin PP
Witamina PP
Β-pyridinecarboxamide
|
|
4 |
|
Simvastatin |
Approved |
Phase 3 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
5 |
|
Atorvastatin |
Approved |
Phase 3 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
ATORVASTATIN
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
Atorvastatina
Atorvastatine
Atorvastatinum
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
|
Cardyl
Faboxim
Hipolixan
Hydrate, atorvastatin calcium
LCF872
Lipitor
Lipitor®
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
Normalip
PREVENCOR
Sincol
Sortis
Sotis
TAHOR
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
Vastina
Xanator
Xarator
Xavator
ZARATOR
Zurinel
|
|
6 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
7 |
|
Niacin |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
59-67-6 |
938 |
Synonyms:
[<sup>3</sup>H]-nicotinic acid
3 Pyridinecarboxylic acid
3-CARBOXYLPYRIDINE
3-CARBOXYPYRIDINE
3-PICOLINIC ACID
3-PYRIDINECARBOXYLATE
3-PYRIDINECARBOXYLIC ACID
3-PYRIDYLCARBOXYLATE
3-PYRIDYLCARBOXYLIC ACID
ACIDE NICOTINIQUE
ACIDO NICOTINICO
ácido nicotínico
ACIDUM NICOTINICUM
AKOTIN
Aluminum salt, niacin
ANTI-PELLAGRA VITAMIN
APELAGRIN
beta-Pyridinecarboxylate
BETA-PYRIDINECARBOXYLIC ACID
b-Pyridinecarboxylate
b-Pyridinecarboxylic acid
DASKIL
EFACIN
ENDURACIN
Hydrochloride, niacin
INDURACIN
LINIC
Lithium nicotinate
m-Pyridinecarboxylate
M-PYRIDINECARBOXYLIC ACID
NIAC
NIACIN
Niacin aluminum salt
Niacin ammonium salt
Niacin calcium salt
Niacin cobalt (2+) salt
Niacin copper (2+) salt
Niacin hydrochloride
Niacin iron (2+) salt
Niacin lithium salt
Niacin lithium salt, hemihydrate
Niacin magnesium salt
Niacin manganese (2+) salt
Niacin potassium salt
Niacin sodium salt
Niacin tartrate
NIACIN TD
Niacin tosylate
Niacin zinc salt
niacin|nicotinate|vitamin B<sub>3</sub>|vitamin PP
Niacina
NIACINE
|
NIACOR
NIASPAN
NIASPAN ER
NIASPAN TITRATION STARTER PACK
NICACID
NICAMIN
NICANGIN
Nico 400
Nico400
Nico-400
NICOBID
NICOCAP
NICODELMINE
NICOLAR
NICONACID
NICOSAN 3
NICO-SPAN
NICOTINATE
Nicotinate, lithium
NICOTINIC ACID
NICOTINIPCA
NICYL
NIKOTINSAEURE
Nikotinsäure
NSC-169454
NYCLIN
P.P. FACTOR
PELLAGRA PREVENTIVE FACTOR
PELLAGRIN
PELONIN
PEVITON
Potassium salt, niacin
PP FACTOR
PYRIDINE-3-CARBOXYLIC ACID
Pyridine-b-carboxylate
Pyridine-b-carboxylic acid
Pyridine-beta-carboxylate
PYRIDINE-BETA-CARBOXYLIC ACID
Pyridine-β-carboxylate
PYRIDINE-Β-CARBOXYLIC ACID
SIMCOR
SLO-NIACIN
Sodium salt, niacin
Tartrate, niacin
TINIC
Tosylate, niacin
VITAMIN B3
VITAMIN PP
WAMPOCAP
Β-pyridinecarboxylate
Β-PYRIDINECARBOXYLIC ACID
|
|
8 |
|
Torcetrapib |
Investigational |
Phase 3 |
|
262352-17-0 |
|
Synonyms:
|
9 |
|
Vitamins |
|
Phase 3 |
|
|
|
10 |
|
Folate |
|
Phase 3 |
|
|
|
11 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
12 |
|
Vitamin B3 |
|
Phase 3 |
|
|
|
13 |
|
Trace Elements |
|
Phase 3 |
|
|
|
14 |
|
Nicotinic Acids |
|
Phase 3 |
|
|
|
15 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
16 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
17 |
|
Micronutrients |
|
Phase 3 |
|
|
|
18 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
20 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
21 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
22 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
23 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
24 |
|
Ezetimibe |
Approved |
Phase 2 |
|
163222-33-1 |
150311 |
Synonyms:
(1-(4-Fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
ABSORCOL
Ezedoc
Ezetimib
Ezetimiba
EZETIMIBE
ézétimibe
|
Ezetimibum
Ezetrol
MK0653
SCH 58235
SCH 58235|SCH-58235|Zetia®
SCH-58235
Zetia
|
|
25 |
|
Eliglustat |
Approved, Investigational |
Phase 2 |
|
491833-29-5 |
11531537 23652731 |
Synonyms:
CERDELGA
ELIGLUSTAT
éliglustat
Eliglustatum
|
GENZ 99067
GENZ-112638
GENZ-99067
N-[(1R,2R)-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-1-HYDROXY-3-(1-PYRROLIDINYL)-2-PROPANYL]OCTANAMIDE
|
|
26 |
|
Phytosterol |
|
Phase 2 |
|
|
|
27 |
|
Gamma-sitosterol |
|
Phase 2 |
|
|
|
28 |
|
Rosuvastatin Calcium |
|
Phase 1 |
|
147098-20-2 |
|
Synonyms:
CRESTOR
EZALLOR
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM SALT
|
S-4522
ZD-4522
ZD-4522 (CALCIUM SALT)
|
|
29 |
|
Liver Extracts |
|
Phase 1 |
|
|
|
30 |
|
Calcium, Dietary |
|
Phase 1 |
|
|
|
31 |
|
Calcium |
Nutraceutical |
Phase 1 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
32 |
|
Fenofibric acid |
Approved |
|
|
42017-89-0 |
64929 |
Synonyms:
FENOCOR-67
Fenofibrate
FENOFIBRATE FREE ACID
FENOFIBRATE RELATED COMPOUND B
FENOFIBRIC ACID
FENOGAL
FIBRICOR
LF-153
|
LIPANTHYL
LIPOFEN
LOFIBRA
NSC-281318
Procetofenate
Procetofenic acid
SUPRALIP
TRILIPIX
|
|
33 |
|
Barley |
Approved |
|
|
|
|
34 |
|
Calcium polycarbophil |
Approved |
|
|
126040-58-2 |
|
Synonyms:
Calcium polycarbophil
Polycarbophil calcium
|
|
|
35 |
|
Infliximab |
Approved |
|
|
170277-31-3 |
|
Synonyms:
ABP 710
BOW015
CA2
CA2 ????
IG GAMMA-1 CHAIN C REGION
INFLECTRA
INFLIXIMAB
Infliximab (genetical recombination)
|
Infliximab-abda
Infliximab-axxq
Infliximab-dyyb
Infliximab-qbtx
NI-071
REMICADE
REMSIMA
TA-650
|
|
36 |
|
Azathioprine |
Approved |
|
|
446-86-6 |
2265 |
Synonyms:
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
Azamun
AZAMUNE
Azanin
AZAPRESS
Azasan
Azathioprin
AZATHIOPRINE
Azathioprine sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azatioprin
Azatioprina
|
Azothioprine
BERKAPRINE
BW-57-322
Ccucol
IMMUNOPRIN 50
Immuran
Imuran
IMURAN (TN)
Imurek
Imurel
KENTAPRINE
Muran
NSC-39084
OPRISINE 50
Sodium, azathioprine
|
|
37 |
|
Psyllium |
|
|
|
|
|
38 |
|
Soy Bean |
|
|
|
|
|
39 |
|
Chrysarobin |
|
|
|
|
|
40 |
|
Antirheumatic Agents |
|
|
|
|
|
41 |
|
Eicosapentaenoic acid ethyl ester |
|
|
|
|
3298 |
Synonyms:
AMR-101
Eicosapentaenoate ethyl ester
Epadel
Ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
Ethyl all-cis-5,8,11,14,17-icosapentaenoate
Ethyl eicosapentaenoate
Ethyl eicosapentaenoic acid
|
Ethyl icosa-5,8,11,14,17-pentaenoic acid
Ethyl icosapentaenoate
Ethyl-eicosapentaenoic acid
Ethyl-epa
Icosapent ethyl
Vascepa
|
|
42 |
|
Gastrointestinal Agents |
|
|
|
|
|
43 |
|
Immunosuppressive Agents |
|
|
|
|
|
44 |
|
Dermatologic Agents |
|
|
|
|
|
45 |
|
Immunologic Factors |
|
|
|
|
|
Interventional clinical trials:
(show all 29)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) |
Completed |
NCT01527318 |
Phase 4 |
Fibrate treatment |
2 |
A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. |
Completed |
NCT00365131 |
Phase 4 |
Cerezyme (imiglucerase for injection) |
3 |
A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease |
Completed |
NCT00364858 |
Phase 4 |
Cerezyme |
4 |
An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia |
Withdrawn |
NCT02069106 |
Phase 4 |
|
5 |
A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia |
Completed |
NCT00269217 |
Phase 3 |
niacin (+) laropiprant (+) simvastatin;Comparator: niacin (+) laropiprant;Comparator: simvastatin |
6 |
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia |
Completed |
NCT00269204 |
Phase 3 |
niacin (+) laropiprant;ER-niacin |
7 |
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia |
Completed |
NCT00289900 |
Phase 3 |
MK-0524A;Atorvastatin;Simvastatin |
8 |
A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency |
Active, not recruiting |
NCT02004691 |
Phase 2, Phase 3 |
placebo (saline);GZ402665 |
9 |
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia |
Terminated |
NCT00134238 |
Phase 3 |
torcetrapib/atorvastatin;atorvastatin |
10 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia |
Completed |
NCT00045812 |
Phase 2 |
SCH-58235 |
11 |
A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency |
Completed |
NCT02292654 |
Phase 1, Phase 2 |
Olipudase alfa |
12 |
A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia |
Completed |
NCT00941603 |
Phase 2 |
SCH 900271 15mg;SCH 900271;Placebo |
13 |
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients |
Completed |
NCT00358150 |
Phase 2 |
Eliglustat tartrate |
14 |
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency |
Active, not recruiting |
NCT02004704 |
Phase 2 |
GZ402665 |
15 |
Effects of Pediatric Liver Adiposity on Statin Disposition and Response |
Recruiting |
NCT04903223 |
Phase 1 |
Rosuvastatin 10mg |
16 |
Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy |
Unknown status |
NCT02635269 |
|
|
17 |
Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy. |
Unknown status |
NCT01974297 |
|
Atorvastatin 10mg, fenofibric acid 135mg;atorvastatin 20mg |
18 |
DASH Dietary Pattern and Cardiometabolic Risk: An Umbrella Review of Systematic Reviews and Meta-analyses of Prospective Cohort Studies and Randomized and Non-randomized Controlled Trials |
Unknown status |
NCT03542370 |
|
|
19 |
Effect of a Portfolio Dietary Pattern on Cardiometabolic Risk: A Systematic Review and Meta-analysis of Controlled Trials |
Unknown status |
NCT03534414 |
|
|
20 |
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD) |
Approved for marketing |
NCT04877132 |
|
olipudase alfa (GZ402665) |
21 |
Study of Physical and Physiological Changes Through the Use of a Mobile App That Promotes Healthy Habits |
Completed |
NCT05093803 |
|
|
22 |
International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases |
Recruiting |
NCT02918032 |
|
|
23 |
Let's Get to Know Your Health Better? Assessment of Lifestyle, Blood Pressure and Cholesterol in the Population of Employees Libbs Farmacêutica LTDA. |
Recruiting |
NCT04373863 |
|
|
24 |
Gaucher Disease Registry Protocol |
Recruiting |
NCT00358943 |
|
|
25 |
Can Mindful Eating Improve Cholesterol and Glucose Level: A Tele-Health Pilot-Randomised Controlled Trial |
Recruiting |
NCT04833595 |
|
|
26 |
A Prospective and Retrospective Cohort Study to Refine and Expand the Knowledge on Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) |
Active, not recruiting |
NCT04106544 |
|
|
27 |
The Investigation of Daily Living Activities and Exercise Capacity in Lipid Storage Diseases |
Not yet recruiting |
NCT03875105 |
|
|
28 |
N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease:a Prospective Randomized Controlled Trial |
Not yet recruiting |
NCT04761952 |
|
azathioprine;infliximab;N-3 Polyunsaturated Fatty Acids |
29 |
Clinical Study on the Safety and Efficacy of Medium-chain Fatty Acid Capsules (CNT-02) for Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Neutral Lipid Storage Disease With Myopathy (NLSD-M) |
Terminated |
NCT02830763 |
|
|
Cochrane evidence based reviews: lipidoses
|